BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29859119)

  • 1. Development and internal validation of PI-RADs v2-based model for clinically significant prostate cancer.
    Zhang Y; Zeng N; Zhu YC; Huang YXR; Guo Q; Tian Y
    World J Surg Oncol; 2018 Jun; 16(1):102. PubMed ID: 29859119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 4. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic value of combining PI-RADS v2.1 with PSAD in clinically significant prostate cancer.
    Wei X; Xu J; Zhong S; Zou J; Cheng Z; Ding Z; Zhou X
    Abdom Radiol (NY); 2022 Oct; 47(10):3574-3582. PubMed ID: 35788882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinical decision-making value of prostate specific antigen and its derived indicators in prostate imaging reporting and data system version 2 3 lesions].
    Yang S; Zhang YY; Zhao WL; Wei CG; Chen T; Li MJ; Tan SX; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Apr; 100(13):997-1001. PubMed ID: 32294856
    [No Abstract]   [Full Text] [Related]  

  • 11. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
    Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
    BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Accuracy and Interobserver Agreement of PI-RADS Version 2 and Version 2.1 for the Detection of Transition Zone Prostate Cancers.
    Wei CG; Zhang YY; Pan P; Chen T; Yu HC; Dai GC; Tu J; Yang S; Zhao WL; Shen JK
    AJR Am J Roentgenol; 2021 May; 216(5):1247-1256. PubMed ID: 32755220
    [No Abstract]   [Full Text] [Related]  

  • 13. [The diagnostic value of version 2.1 prostate imaging reporting and data system for prostate transitional zone lesions].
    Yang S; Zhang CY; Zhang YY; Tan SX; Wei CG; Shen XH; Shen JK
    Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3609-3613. PubMed ID: 33333685
    [No Abstract]   [Full Text] [Related]  

  • 14. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
    Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
    Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Prostate Imaging Reporting and Data System, Histogram Analysis, and Prostate-Specific Antigen Density to Determine the Risk of Prostate Cancer in Patients With Prostate-Specific Antigen of 4 to 20 ng/mL.
    Liu X; Deng L; Zhou L; Peng W
    J Comput Assist Tomogr; 2019; 43(4):645-651. PubMed ID: 31268875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The value of machine learning models based on biparametric MRI for diagnosis of prostate cancer and clinically significant prostate cancer].
    Qiao XM; Hu CH; Hu S; Hu CH; Wang XM; Shen JK; Ji LB; Song Y; Bao J
    Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1446-1454. PubMed ID: 37198106
    [No Abstract]   [Full Text] [Related]  

  • 17. Development and external validation of a novel nomogram to predict prostate cancer in biopsy-naïve patients with PSA <10 ng/ml and PI-RADS v2.1 = 3 lesions.
    Hu C; Sun J; Xu Z; Zhang Z; Zhou Q; Xu J; Chen H; Wang C; Ouyang J
    Cancer Med; 2023 Feb; 12(3):2560-2571. PubMed ID: 35920264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performing Precise Biopsy in Naive Patients With Equivocal PI-RADS, Version 2, Score 3, Lesions: An MRI-based Nomogram to Avoid Unnecessary Surgical Intervention.
    Zhang Y; Zeng N; Zhang FB; Rui Huang YX; Tian Y
    Clin Genitourin Cancer; 2020 Oct; 18(5):367-377. PubMed ID: 32771334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a predictive model for clinically significant prostate cancer by combining age, PSA density, and mpMRI.
    Ma Z; Wang X; Zhang W; Gao K; Wang L; Qian L; Mu J; Zheng Z; Cao X
    World J Surg Oncol; 2023 Mar; 21(1):83. PubMed ID: 36882854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer.
    Deniffel D; Healy GM; Dong X; Ghai S; Salinas-Miranda E; Fleshner N; Hamilton R; Kulkarni G; Toi A; van der Kwast T; Zlotta A; Finelli A; Perlis N; Haider MA
    Radiology; 2021 Aug; 300(2):369-379. PubMed ID: 34032510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.